""We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers.""
""Research strongly shows that apolipoprotein B (apoB) is better at identifying who is at risk, because it counts the total number of harmful particles in the blood.""
A study indicates that apolipoprotein B (apoB) testing is superior to traditional LDL and non-HDL cholesterol tests in guiding cholesterol-lowering treatments. This method can prevent more heart attacks and strokes while being cost-effective for healthcare payers. Heart disease, a leading cause of death in the U.S., is linked to cholesterol-carrying particles that form arterial plaques. ApoB testing provides a better risk assessment by counting harmful particles in the blood, yet it remains underutilized due to cost and convenience issues.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]